Our top pick for
Amyris Inc is a specialty chemicals business based in the US. Amyris shares (AMRS) are listed on the NASDAQ and all prices are listed in US Dollars. Amyris employs 595 staff and has a trailing 12-month revenue of around 0.00.
|Latest market close||$13.96|
|52-week range||$1.88 - $23.42|
|50-day moving average||$13.27|
|200-day moving average||$14.34|
|Wall St. target price||$22.83|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||$-1.81|
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
|1 week (2021-10-21)||-1.48%|
|1 month (2021-09-28)||2.27%|
|3 months (2021-07-28)||-7.37%|
|6 months (2021-04-28)||-9.11%|
|1 year (2020-10-28)||418.96%|
|2 years (2019-10-28)||278.32%|
|3 years (2018-10-26)||99.43%|
|5 years (2016-10-28)||1,229.52%|
Valuing Amyris stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Amyris's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
Amyris's EBITDA (earnings before interest, taxes, depreciation and amortisation) is $11.1 million.
The EBITDA is a measure of a Amyris's overall financial performance and is widely used to measure a its profitability.
|Revenue TTM||$343.2 million|
|Gross profit TTM||$14.8 million|
|Return on assets TTM||-2.22%|
|Return on equity TTM||0%|
|Market capitalisation||$4.3 billion|
TTM: trailing 12 months
There are currently 21.7 million Amyris shares held short by investors – that's known as Amyris's "short interest". This figure is 3.5% up from 21.0 million last month.
There are a few different ways that this level of interest in shorting Amyris shares can be evaluated.
Amyris's "short interest ratio" (SIR) is the quantity of Amyris shares currently shorted divided by the average quantity of Amyris shares traded daily (recently around 3.0 million). Amyris's SIR currently stands at 7.17. In other words for every 100,000 Amyris shares traded daily on the market, roughly 7170 shares are currently held short.
However Amyris's short interest can also be evaluated against the total number of Amyris shares, or, against the total number of tradable Amyris shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Amyris's short interest could be expressed as 0.07% of the outstanding shares (for every 100,000 Amyris shares in existence, roughly 70 shares are currently held short) or 0.1106% of the tradable shares (for every 100,000 tradable Amyris shares, roughly 111 shares are currently held short).
A SIR below 10% would generally be considered to indicate a fairly optimistic outlook for the share price, with fewer people currently willing to bet against Amyris.
Find out more about how you can short Amyris stock.
We're not expecting Amyris to pay a dividend over the next 12 months.
Amyris's shares were split on a 1:15 basis on 5 June 2017. So if you had owned 15 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Amyris shares – just the quantity. However, indirectly, the new 1400% higher share price could have impacted the market appetite for Amyris shares which in turn could have impacted Amyris's share price.
Over the last 12 months, Amyris's shares have ranged in value from as little as $1.88 up to $23.42. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Amyris's is 1.2402. This would suggest that Amyris's shares are a little bit more volatile than the average for this exchange and represent, relatively-speaking, a slightly higher risk (but potentially also market-beating returns).
Amyris, Inc. , a synthetic biotechnology company, operates in the clean health and beauty markets through its consumer brands and as a supplier of sustainable and natural ingredients in Europe, the United States, Asia, Brazil, and internationally. It manufactures and sells products for the health and wellness, clean beauty, and flavor and fragrance markets. The company operates under the Amyris, Biofene, Biossance, Pipette, Purecane, and No Compromise trademarks. Amyris, Inc. has a collaboration agreement with the Infectious Disease Research Institute to advance a novel ribonucleic acid vaccine platform, including accelerating the development of a COVID-19 vaccine. The company was formerly known as Amyris Biotechnologies, Inc.
Steps to owning and managing ProShares Bitcoin Strategy ETF units.
Everything we know about the The Real Good Food Company IPO, plus information on how to buy in.
Everything we know about the Lulu’s Fashion Lounge Holdings IPO, plus information on how to buy in.
Everything we know about the Allarity Therapeutics IPO, plus information on how to buy in.
Everything we know about the Jupiter Neurosciences IPO, plus information on how to buy in.
Everything we know about the Mainz Biomed IPO, plus information on how to buy in.
Everything we know about the Progressive Care IPO, plus information on how to buy in.
Everything we know about the Desert Peak Minerals IPO, plus information on how to buy in.
Everything we know about the Vaxxinity IPO, plus information on how to buy in.
Everything we know about the Entrada Therapeutics IPO, plus information on how to buy in.
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.